We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
+28.34%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$15.2B
AUM Growth
+$1.87B
Cap. Flow
+$90.5M
Cap. Flow %
0.6%
Top 10 Hldgs %
84.66%
Holding
125
New
12
Increased
14
Reduced
21
Closed
27

Top Buys

Rank Stock Value
1
PRNB
Principia Biopharma Inc. Common Stock
PRNB
+$50.5M
2
AMRN
Amarin Corp
AMRN
+$43.1M
3
INSM icon
Insmed
INSM
+$26M
4
ACAD icon
Acadia Pharmaceuticals
ACAD
+$19M
5
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$10.8M

Top Sells

Rank Stock Value
1
BLUE
bluebird bio
BLUE
+$22.4M
2
PHXM
PHAXIAM Therapeutics S.A.. American Depositary Shares
PHXM
+$20.8M
3
HALO icon
Halozyme
HALO
+$14.6M
4
EXEL icon
Exelixis
EXEL
+$11M
5
XNCR icon
Xencor
XNCR
+$11M

Sector Composition

Rank Sector Weight
1 Healthcare 91.42%
2 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ADMS
76
DELISTED
Adamas Pharmaceuticals
ADMS
$3.46M 0.02%
172,630
– –
ARAV
77
DELISTED
Aravive, Inc. Common Stock
ARAV
$3.4M 0.02%
404,385
– –
RARX
78
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$3.22M 0.02%
177,952
– –
LJPC
79
DELISTED
La Jolla Pharmaceutical Company
LJPC
$3.11M 0.02%
154,675
– –
TRIL
80
DELISTED
Trillium Therapeutics Inc.
TRIL
$2.93M 0.02%
505,262
-6,501
-1% -$36.6K
KRYS icon
81
Krystal Biotech
KRYS
$10.7B
$2.02M 0.01%
114,674
-85,326
-43% -$1.43M
AQST icon
82
Aquestive Therapeutics
AQST
$465M
$1.74M 0.01%
+99,600
New +$1.64M
RCUS icon
83
Arcus Biosciences
RCUS
$3.33B
$1.69M 0.01%
121,534
– –
INFI
84
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$1.57M 0.01%
580,400
– –
MTEM
85
DELISTED
Molecular Templates, Inc.
MTEM
$1.37M 0.01%
16,949
+12,122
+251% +$929K
OVID icon
86
Ovid Therapeutics
OVID
$427M
$1.26M 0.01%
222,139
-25,594
-10% -$194K
VIRX
87
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$1.11M 0.01%
15,905
– –
DVAX
88
DELISTED
Dynavax Technologies
DVAX
$930K 0.01%
75,000
– –
CNST
89
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
$897K 0.01%
+133,333
New +$1.27M
AFMD
90
DELISTED
Affimed
AFMD
$870K 0.01%
20,000
-20,000
-50% -$567K
TARA icon
91
Protara Therapeutics
TARA
$216M
$582K ﹤0.01%
7,465
– –
AIXC
92
AIxCrypto Holdings Inc
AIXC
$13.4M
$521K ﹤0.01%
22
– –
FLGT icon
93
Fulgent Genetics
FLGT
$563M
$491K ﹤0.01%
125,000
– –
ABUS icon
94
Arbutus Biopharma
ABUS
$853M
– –
-180,582
Closed -$1.32M
ADAP
95
DELISTED
Adaptimmune Therapeutics
ADAP
– –
-100,000
Closed -$1.19M
AKTX
96
Akari Therapeutics
AKTX
$14.7M
– –
-73
Closed -$115K
CARM
97
DELISTED
Carisma Therapeutics
CARM
– –
-131,221
Closed -$5.12M
CLLS
98
Cellectis
CLLS
$289M
– –
-50,000
Closed -$1.42M
CRBP icon
99
Corbus Pharmaceuticals
CRBP
$169M
– –
-8,248
Closed -$1.25M
BGMSP
100
DELISTED
Bio Green Med Solution Inc Preferred Stock
BGMSP
– –
-13,253
Closed -$89K
1 2 3
4
5

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q3 2018 Portfolio in Review

As of Q3 2018, Baker Bros. Advisors held 125 positions worth $15.2B, up 14% from $13.3B the previous quarter. Its ten largest holdings account for 85% of the portfolio.

Baker Bros. Advisors's Q3 2018 filing shows 12 new, 14 increased, 21 reduced and 27 closed positions. Its largest new stake was Principia Biopharma Inc. Common Stock: 1,787,807 shares worth $52.2M. The largest sale was bluebird bio, an estimated $22.4M.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, down from 92% a quarter earlier, followed by Technology.

  • Baker Bros. Advisors's largest Q3 2018 buy was Principia Biopharma Inc. Common Stock: 1,787,807 shares worth $52.2M.
  • Baker Bros. Advisors added most to Amarin Corp in Q3 2018, an estimated $43.1M increase.
  • Baker Bros. Advisors's biggest Q3 2018 reduction was bluebird bio, cutting an estimated $22.4M.
  • Baker Bros. Advisors fully exited Exelixis in Q3 2018, selling an estimated $11M.
  • Baker Bros. Advisors's ten largest holdings make up 85% of its $15.2B portfolio in Q3 2018.
  • Baker Bros. Advisors opened 12 new positions and closed 27 in Q3 2018.
  • Baker Bros. Advisors's portfolio value rose 14% quarter-over-quarter to $15.2B.

Based on Baker Bros. Advisors's 13F filing for Q3 2018, filed 14 Nov 2018.